VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes
July 01 2019 - 08:00AM
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage
biopharmaceutical company developing next-generation infectious
disease and immuno-oncology vaccines, announced today that it has
been added to the Russell 2000® and the Russell 3000® Indexes
following the annual reconstitution, effective after the US market
opens on Monday, July 1, 2019.
Annual reconstitution of the Russell US Indexes
captures the 4,000 largest US stocks as of May 10, ranking them by
total market capitalization. Membership in the Russell 3000® Index,
which remains in place for one year, means automatic inclusion in
the large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell US
Indexes primarily by objective, market-capitalization rankings, and
style attributes.
The Russell US Indexes are widely used by
investment managers and institutional investors for passive funds
and investment products and as benchmarks for active investment
strategies. Approximately $9 trillion in assets are benchmarked
against Russell US Indexes. Russell US Indexes are part of FTSE
Russell’s suite of index offerings.
For more information on the Russell 3000® Index
and the Russell US Indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About VBI Vaccines
Inc.
VBI Vaccines Inc. (Nasdaq: VBIV) is a
commercial-stage biopharmaceutical company developing a next
generation of vaccines to address unmet needs in infectious disease
and immuno-oncology. VBI is advancing the prevention and treatment
of hepatitis B, with the only commercially-approved trivalent
hepatitis B vaccine, Sci-B-Vac®, which is approved for use in
Israel and 10 other countries and is currently in a Phase 3 program
in the U.S., Europe, and Canada, and with an immunotherapeutic in
development for a functional cure for chronic hepatitis B. VBI’s
eVLP Platform technology allows for the development of enveloped
virus-like particle (eVLP) vaccines that closely mimic the target
virus to elicit a potent immune response. Integrating its
cytomegalovirus (CMV) expertise with the eVLP platform technology,
VBI’s lead eVLP program candidates include a prophylactic CMV
vaccine candidate and a glioblastoma (GBM) vaccine
immunotherapeutic candidate. VBI is headquartered in Cambridge, MA
with research operations in Ottawa, Canada and research and
manufacturing facilities in Rehovot, Israel.
Website Home:
http://www.vbivaccines.com/
News and Insights:
http://www.vbivaccines.com/wire/
Investors:
http://www.vbivaccines.com/investors/
VBI
Contact
Nicole AndersonAssociate, Corporate
CommunicationsPhone: (617) 830-3031 x124Email:
info@vbivaccines.com
VBI Investor
Contact
Nell BeattieChief Business OfficerEmail:
ir@vbivaccines.com
VBI Media
Contact
Burns McClellan, Inc.Robert Flamm, Ph.D.Phone:
(212) 213-0006Email: rflamm@burnsmc.com
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Feb 2024 to Mar 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Mar 2023 to Mar 2024